- Home
- LFCR vs TVRD Comparison
LFCR vs TVRD Comparison
Compare LFCR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFCR
- TVRD
- Stock Information
- Founded
- LFCR 1986
- TVRD 2017
- Country
- LFCR United States
- TVRD United States
- Employees
- LFCR N/A
- TVRD N/A
- Industry
- LFCR Biotechnology: Pharmaceutical Preparations
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- LFCR Health Care
- TVRD Health Care
- Exchange
- LFCR Nasdaq
- TVRD Nasdaq
- Market Cap
- LFCR 288.0M
- TVRD 246.5M
- IPO Year
- LFCR N/A
- TVRD N/A
- Fundamental
- Price
- LFCR $6.52
- TVRD $42.40
- Analyst Decision
- LFCR Buy
- TVRD Strong Buy
- Analyst Count
- LFCR 4
- TVRD 5
- Target Price
- LFCR $8.00
- TVRD $59.20
- AVG Volume (30 Days)
- LFCR 215.7K
- TVRD 72.3K
- Earning Date
- LFCR 10-03-2025
- TVRD 11-21-2025
- Dividend Yield
- LFCR N/A
- TVRD N/A
- EPS Growth
- LFCR N/A
- TVRD N/A
- EPS
- LFCR N/A
- TVRD N/A
- Revenue
- LFCR $128,867,000.00
- TVRD N/A
- Revenue This Year
- LFCR $4.71
- TVRD N/A
- Revenue Next Year
- LFCR $10.98
- TVRD N/A
- P/E Ratio
- LFCR N/A
- TVRD N/A
- Revenue Growth
- LFCR 0.47
- TVRD N/A
- 52 Week Low
- LFCR $4.33
- TVRD $8.13
- 52 Week High
- LFCR $8.85
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- LFCR 35.31
- TVRD 68.05
- Support Level
- LFCR $6.72
- TVRD $39.13
- Resistance Level
- LFCR $7.46
- TVRD $42.10
- Average True Range (ATR)
- LFCR 0.41
- TVRD 2.87
- MACD
- LFCR -0.08
- TVRD 0.11
- Stochastic Oscillator
- LFCR 4.52
- TVRD 79.98
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.